Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.

Azenta posts strong revenue growth but remains unprofitable despite robust cash reserves.

What the company is saying

Azenta, Inc. presents its third quarter 2026 results as evidence of operational momentum, highlighting a 12% year-over-year revenue increase to $161 million from continuing operations. The narrative emphasizes double-digit growth in both Sample Management Solutions (up 14%) and Multiomics (up 10%), positioning these segments as key drivers. Management draws attention to a solid cash position of $529 million and the repurchase of 2.3 million shares for $50 million, framing these as signals of financial strength and shareholder alignment. Forward-looking statements project full-year 2026 revenue of $613–$618 million and adjusted EBITDA of $59–$62 million, with free cash flow expected to improve 10%–15% year-over-year. The tone is measured and factual, avoiding promotional language, but omits detailed discussion of the persistent operating loss and provides no product-level or customer breakdowns. CEO John Marotta is referenced, but no specific commentary or institutional signaling is attached to his involvement.

What the data suggests

Reported revenue of $161 million for the quarter marks a 12% increase from the prior year, with organic revenue up 9% after adjusting for foreign exchange and acquisitions. Sample Management Solutions contributed $88 million (up 14%), and Multiomics added $73 million (up 10%), confirming broad-based segment growth. Despite these gains, the company posted an operating loss of $4.2 million and a negative free cash flow of $5 million, indicating that revenue expansion has not yet translated to sustained profitability. Adjusted EBITDA was $18.5 million, yielding an 11.4% margin, while gross margin stood at 44.9%. Operating expenses rose 12% to $77 million, matching the pace of revenue growth and limiting margin improvement. The company’s $529 million cash balance provides a significant liquidity buffer, and the $50 million share repurchase demonstrates active capital management. Guidance for full-year revenue ($613–$618 million) and adjusted EBITDA ($59–$62 million) implies continued modest growth, but organic revenue is forecast to be flat to up 1%, signaling a potential slowdown.

Analysis

The announcement is a standard quarterly earnings release, presenting realised financial results for the third quarter of 2026 with clear numerical support for revenue, segment growth, margins, and cash position. While there is some forward-looking guidance for fiscal 2026, the majority of claims are realised and supported by disclosed data. The tone is factual and avoids promotional language, with no exaggerated claims about future performance or outsized benefits. The company does disclose an operating loss, but also provides adjusted EBITDA and margin figures, meeting the disclosure completeness rule for a weak_positive signal. There is no evidence of narrative inflation or overstatement, and capital outlays (such as share repurchases) are matched by immediate, disclosed actions rather than long-dated, uncertain returns.

Risk flags

• ●Sustained operating losses despite double-digit revenue growth raise concerns about the company’s ability to achieve lasting profitability. The $4.2 million operating loss and negative free cash flow of $5 million for the quarter indicate that cost structures remain high relative to revenue.
• ●Guidance for organic revenue growth is muted, with fiscal 2026 expected to be flat to up 1%. This suggests that the recent growth surge may not be sustainable, and future performance could stagnate without new drivers.
• ●The announcement omits detailed breakdowns by customer, product, or geography, and does not reconcile forward-looking non-GAAP measures to GAAP, limiting transparency and making it harder for investors to assess underlying business quality.
• ●Operating expenses increased 12% year over year, matching revenue growth and constraining margin improvement. Without a clear plan to control costs, margin expansion targets may be difficult to achieve.
• ●While the company repurchased $50 million in shares, this capital return does not offset the lack of underlying profitability. Share buybacks can support the stock price in the short term but are not a substitute for operational improvements.

Bottom line

Azenta’s Q3 2026 results show strong top-line growth across both core segments and a sizable cash reserve, but the company remains unprofitable with negative free cash flow. Management’s guidance for the full year is modest, with organic revenue growth expected to stall and margin gains dependent on tighter cost controls. The lack of detailed disclosures on customers, products, or reconciliation of non-GAAP guidance leaves some questions unanswered about the sustainability of performance. While the $50 million share repurchase signals confidence and provides near-term support, it does not address the fundamental challenge of turning revenue growth into consistent profits. Investors should focus on whether Azenta can translate its revenue momentum into positive operating leverage and free cash flow in the coming quarters. The most important takeaway is that revenue growth alone is not yet delivering bottom-line results.

Announcement summary

(NASDAQ:AZTA) Azenta, Inc. reported financial results for the third quarter ended June 30, 2026, with revenue from continuing operations of $161 million, up 12% year over year. Organic revenue increased 9% year over year, excluding a 1-percentage point impact from foreign exchange and a 3-percentage point impact from the acquisition of UK Biocentre Limited. Sample Management Solutions revenue was $88 million, up 14% year over year, and Multiomics revenue was $73 million, up 10% year over year. Adjusted EBITDA for continuing operations was $18.5 million, with an adjusted EBITDA margin of 11.4%. The company ended the quarter with $529 million in cash, cash equivalents, restricted cash, and marketable securities, and repurchased 2.3 million shares of common stock for $50.0 million under its 2025 Repurchase Program. The company projects total reported revenue from continuing operations for fiscal 2026 to range between $613 to $618 million, adjusted EBITDA to be in the range of $59 million to $62 million, and free cash flow to improve approximately 10% to 15% year-over-year. The company also expects total organic revenue for fiscal 2026 to range between flat to up 1% compared to fiscal 2025.

Disagree with this article?